Company news

Cue Biopharma, Inc. news in 2021

Cue Biopharma, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

December 14, 2021

Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

November 11, 2021

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

October 20, 2021

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

October 3, 2021

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

September 27, 2021

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

September 20, 2021

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

August 16, 2021

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

June 9, 2021

Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

May 16, 2021

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

May 9, 2021

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

March 15, 2021

Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos

February 24, 2021

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

February 16, 2021

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

February 7, 2021

Decks in 2021